Vertex Pharmaceuticals Inc (VRTX)

75.55
0.05 0.07
NASDAQ : Health Care
Prev Close 75.50
Open 76.13
Day Low/High 75.25 / 77.33
52 Wk Low/High 75.90 / 143.45
Volume 2.56M
Avg Volume 1.91M
Exchange NASDAQ
Shares Outstanding 248.03M
Market Cap 19.30B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017

Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the results of a Phase 3 study of ORKAMBI ® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of...

Vertex To Present At The Credit Suisse Healthcare Conference On November 8

Vertex To Present At The Credit Suisse Healthcare Conference On November 8

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.

Vertex Pharmaceuticals Enters Oversold Territory

Vertex Pharmaceuticals Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test

ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test

The development of QR-010 is still early but Thursday's preliminary study results were encouraging enough to boost ProQR's stock price.

Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF

Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) show the potential to...

Vertex Pharma (VRTX) Stock Lower on Q3 Miss

Vertex Pharma (VRTX) Stock Lower on Q3 Miss

Vertex Pharma (VRTX) reported lower-than-expected results for the third quarter late yesterday.

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.

Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials

Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials

Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.

Vertex Reports Third Quarter 2016 Financial Results

Vertex Reports Third Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2016 and reviewed recent progress with its approved and investigational cystic...

Table 1 (Graphic: Vertex)

Table 1 (Graphic: Vertex)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with...

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina fell 24% on news that it was cutting revenue guidance.

Vertex To Announce Third Quarter 2016 Financial Results On October 25

Vertex To Announce Third Quarter 2016 Financial Results On October 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close.

When Does Vertex Pharmaceuticals Become a Buy?

When Does Vertex Pharmaceuticals Become a Buy?

Vertex Pharmaceuticals shares are down 31% year to date. Investors are wondering if they should hang on, buy or wait.

Vertex To Present At Upcoming Investor Conferences

Vertex To Present At Upcoming Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

Vertex Pharmaceuticals Takes Over #81 Spot From Starbucks

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Vertex Pharmaceuticals, Inc. has taken over the #81 spot from Starbucks Corp.

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Provides Update On Ongoing Phase 3 Program For VX-661 In Combination With Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies...

Listen Up and Pay Attention to the Utes

This is where a lot of money has been parked in the last year.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second Quarter 2016 Financial Results

Vertex Reports Second Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic fibrosis...

A 'Semi-Charmed' Kind of NXPI Call Spread

A 'Semi-Charmed' Kind of NXPI Call Spread

It might be best to make this a late-afternoon purchase.

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex To Announce Second Quarter 2016 Financial Results On July 27

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.